Lytone Enterprise, Inc.
TTPEX:129324.05
TWD
0.00
(0.00%)
ISIN
TW0001293009
Return %
Stock
S&P 500
1Y
-12.23
14.20
3Y
-19.57
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Yan Lin
- Full Time Employees
- 57
- Sector
- Technology services
- Industry
- Information technology services
- Address
- No. 31-1, Lane 169, Kangning St. New Taipei TP Taiwan 22180
- IPO Date
- Oct 29, 2021
- Website
- lytone.com
- Similar Companies
- Business
- Lytone Enterprise, Inc. (1293.TWO) engages in the research, design, development, and commercialization of functional food products, animal husbandry biotechnology solutions, and agricultural biotechnology products in Taiwan. Founded in 1994 by William T.H. Chang Ph.D. and headquartered in Xizhi District, New Taipei City, Taiwan, the company offers post-harvest preservation techniques such as LytoFresh protocols and AnsiP-Sticker; functional fertilizers; livestock feed additives including immune stimulators, growth promoters, and health improvement products; food ingredients comprising plant extracts, animal tissue extracts, probiotics like patented Lactobacillus paracasei LT12, and branded formulations such as Stanxin and Lytodark; and healthy foods targeting metabolic syndrome improvements, skin and hair care, neuroprotection, gastrointestinal care, and allergy relief. It provides OEM/ODM services, CDMO capabilities for functional food formulas, and eco-friendly agriculture and livestock novelty solutions, serving growers, packers, retailers, and end customers globally. Operations span Taiwan, China via subsidiary Shanghai Lytone Biochemicals Ltd., Europe, the United States, Japan, Korea, Southeast Asia, New Zealand, Australia, and East Africa. Recent developments include the debut of patented strain LT12's multifunctional uric acid-lowering research results at the 19th International Symposium on Probiotics and Health in May 2024; a strategic partnership with Ming Chyi Biotechnology Ltd. in November 2022 to advance globalized probiotic services; receipt of the 2022 Taiwan BIO Award for Emerging Company of the Year; and listing on the Taipei Exchange Emerging Stock Market following its initial public offering under stock code 1293.